DEFICIENCY OF MYELOID PHD PROTEINS AGGRAVATES ATHEROGENESIS

DEFICIENCY OF MYELOID PHD PROTEINS AGGRAVATES ATHEROGENESIS VIA MACROPHAGE APOPTOSIS AND PARACRINE FIBROTIC SIGNALING: Atherogenic results of myeloid PHD knockdown
Goals: Atherosclerotic plaque hypoxia is detrimental for macrophage operate. Prolyl hydroxylases (PHDs) provoke mobile hypoxic responses, presumably influencing macrophage operate in plaque hypoxia. Thus, we aimed to elucidate the position of myeloid PHDs in atherosclerosis.
Strategies & outcomes: Myeloid particular PHD knockout (PHDko) mice had been obtained through bone marrow transplantation (PHD1ko, PHD3ko) or conditional knockdown by means of lysozyme M-driven Cre recombinase (PHD2cko). Mice had been fed excessive ldl cholesterol eating regimen for 6-12 weeks to induce atherosclerosis. Aortic root plaque measurement was considerably augmented 2.6-fold in PHD2cko, and 1.4-fold in PHD3ko in comparison with controls, however was unchanged in PHD1ko mice. Macrophage apoptosis was promoted in PHD2cko and PHD3ko mice in vitro and in vivo, through the HIF1α/BNIP3 axis. Bulk and single cell RNA knowledge of PHD2cko bone-marrow-derived macrophages (BMDM) and plaque macrophages, respectively, confirmed enhanced HIF1α/BNIP3 signaling, which was validated in vitro by siRNA silencing. Human plaque BNIP3 mRNA was positively related to plaque necrotic core measurement, suggesting comparable pro-apoptotic results in human.
Additional, PHD2cko plaques displayed enhanced fibrosis, whereas macrophage collagen breakdown by matrix metalloproteinases, collagen manufacturing and proliferation had been unaltered. As an alternative, PHD2cko BMDMs enhanced fibroblast collagen secretion in a paracrine method. In silico evaluation of macrophage-fibroblast communication predicted SPP1 (osteopontin) signaling as regulator, which was corroborated by enhanced plaque SPP1 protein in vivo. Elevated SPP1 mRNA expression upon PHD2cko was preferentially noticed in foamy plaque macrophages expressing “triggering receptor expressed on myeloid cells-2” (TREM2hi) evidenced by single-cell RNA, however not in neutrophils. This confirmed enhanced fibrotic signaling by PHD2cko macrophages to fibroblasts, in vitro in addition to in vivo.
Conclusion: Myeloid PHD2cko and PHD3ko enhanced atherosclerotic plaque progress and macrophage apoptosis, whereas PHD2cko macrophages additional activated collagen secretion by fibroblasts in vitro, possible through paracrine SPP1 signaling by means of TREM2hi macrophages.
Translational outlook: This research exhibits that myeloid PHD isoforms PHD2 and PHD3 worsen plaque traits and phenotype, corresponding to plaque measurement, macrophage accumulation, apoptosis, and collagen accumulation in mice. We present each direct results on macrophages and paracrine results of macrophage PHD2 loss on vessel wall fibroblast populations. Broad spectrum-PHD inhibitors, e.g. Roxadustat, are presently being prescribed to power kidney illness sufferers, who’re already in danger for heart problems. When contemplating this research and the pro-fibrotic and pro-apoptotic results we report, broad PHD inhibition might due to this fact be sub-optimal and extra focused PHD inhibition of PHD1 must be thought of.
The results of various temperatures of post-exercise protein-containing drink on gastric motility and power consumption in wholesome younger males
The current research examined the consequences of various temperatures of protein-containing drink after train on subsequent gastric motility and power consumption in wholesome younger males. Twelve wholesome younger males accomplished three, one-day trials in a random order. In all trials, the topics ran on a treadmill for 30 min at 80% of most coronary heart fee. In train + chilly drink (2 °C) and train + sizzling drink (60 °C) trials, the topics consumed 300 mL of protein-containing drink (0.34 MJ) at 2 °C or 60 °C over a 5-min interval after train. Within the train (i.e., no preload) trial, the topics sat on a chair for five min after train. Then, the topics sat on a chair for 30 min to measure their gastric motility with an ultrasound imaging system in all trials.
Thereafter, the topics consumed a take a look at meal till they felt comfortably full. Vitality consumption within the train + sizzling drink trial was 14 % and 15 % greater than the train (P=0.046, 95% CI: 4.010-482.538) trial and train + chilly drink (P=0.001, 95% CI: 160.089-517.111) trial, respectively. The frequency of the gastric contractions within the train + sizzling drink trial was greater than the train (P=0.023) trial and train + chilly drink (P=0.007) trial. The overall frequency of gastric contractions was positively associated to power consumption (r=0.386, P=0.022). These findings reveal that consuming protein-containing drink after train at 60 °C will increase power consumption and that this improve could also be associated to the modulation of the gastric motility.

Anti-Total Goat Milk Proteins |
|||
4042-PA | Cygnus Technologies | 1 ml | EUR 585.6 |
Description: Anti-Total Goat Milk Proteins by Cygnus Technologies is available in Europe via Gentaur. |
Goat Milk Proteins Sample Diluent |
|||
F243A | Cygnus Technologies | 1000 ml | EUR 678 |
Description: Goat Milk Proteins Sample Diluent by Cygnus Technologies is available in Europe via Gentaur. |
Goat Milk Proteins Sample Diluent |
|||
F243A-100 | Cygnus Technologies | 100 ml | EUR 308.4 |
Description: Goat Milk Proteins Sample Diluent by Cygnus Technologies is available in Europe via Gentaur. |
Goat Milk Proteins Sample Diluent |
|||
F243A-500 | Cygnus Technologies | 500 ml | EUR 493.2 |
Description: Goat Milk Proteins Sample Diluent by Cygnus Technologies is available in Europe via Gentaur. |
Goat Milk Proteins Antigen Concentrate |
|||
F243H | Cygnus Technologies | 100 ul | EUR 493.2 |
Description: Goat Milk Proteins Antigen Concentrate by Cygnus Technologies is available in Europe via Gentaur. |
Goat Milk Proteins Control Antigen |
|||
F247 | Cygnus Technologies | 50 ul | EUR 308.4 |
Description: Goat Milk Proteins Control Antigen by Cygnus Technologies is available in Europe via Gentaur. |
Total Goat Milk Proteins ELISA kit |
|||
F240 | Cygnus Technologies | 1 kit (96 wells plate) | EUR 1296 |
Description: Total Goat Milk Proteins ELISA kit by Cygnus Technologies is available in Europe via Gentaur. |
Total Goat Milk Proteins WB kit |
|||
F245 | Cygnus Technologies | 1 kit (application dependant amount of reactions) | EUR 1003.2 |
Description: Total Goat Milk Proteins WB kit by Cygnus Technologies is available in Europe via Gentaur. |
Rabbit Polyclonal antibody Anti-CRBN |
|||
Anti-CRBN | ImmunoStep | 50 µg | EUR 418.8 |
Human milk specific allergen antibody(IgE) ELISA Kit |
|||
CSB-E15859h-24T | Cusabio | 1 plate of 24 wells | EUR 198 |
Description: Quantitativesandwich ELISA kit for measuring Human milk specific allergen antibody (IgE) in samples from serum, plasma, cell culture supernates, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price. |
Human milk specific allergen antibody(IgE) ELISA Kit |
|||
1-CSB-E15859h | Cusabio |
|
|
Description: Quantitativesandwich ELISA kit for measuring Human milk specific allergen antibody(IgE) in samples from serum, plasma, cell culture supernates, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits. |
Anti-milk fat globulin antibody |
|||
STJ16100177 | St John's Laboratory | 100 µg | EUR 487.2 |
Anti-Goat Milk Proteins:HRP Conjugate |
|||
F241 | Cygnus Technologies | 12 ml | EUR 585.6 |
Description: Anti-Goat Milk Proteins:HRP Conjugate by Cygnus Technologies is available in Europe via Gentaur. |
Anti-Bovine Plasma Proteins |
|||
BPP04 | Cygnus Technologies | 1 ml | EUR 400.8 |
Description: Anti-Bovine Plasma Proteins by Cygnus Technologies is available in Europe via Gentaur. |
Anti-Bovine Plasma Proteins |
|||
BPP04-AF | Cygnus Technologies | 1 mg | EUR 2295.6 |
Description: Anti-Bovine Plasma Proteins by Cygnus Technologies is available in Europe via Gentaur. |
Anti-Bovine Plasma Proteins |
|||
BPP04-PA | Cygnus Technologies | 1 ml | EUR 585.6 |
Description: Anti-Bovine Plasma Proteins by Cygnus Technologies is available in Europe via Gentaur. |
Anti-Bovine Plasma Proteins |
|||
BPP04AF-HRP | Cygnus Technologies | 100 ul | EUR 1186.8 |
Description: Anti-Bovine Plasma Proteins by Cygnus Technologies is available in Europe via Gentaur. |
Skim Milk |
|||
abx082021-100g | Abbexa | 100 g | EUR 260.4 |
Lys proteins Antibody |
|||
ABD2705 | Lifescience Market | 100 ug | EUR 525.6 |
Lys proteins Antibody |
|||
abx219526-100ug | Abbexa | 100 ug | EUR 526.8 |
Lys proteins Antibody |
|||
DF2705 | Affbiotech | 200ul | EUR 420 |
Polyclonal Goat anti-GST α-form |
|||
GST-ANTI-1 | Detroit R&D | 50 uL | EUR 336 |
Polyclonal Goat anti-GST μ-form |
|||
GST-ANTI-2 | Detroit R&D | 50 uL | EUR 336 |
Polyclonal Goat anti-GST p-form |
|||
GST-ANTI-3 | Detroit R&D | 50 uL | EUR 336 |
anti-Human Milk Fat Globule 1 |
|||
YF-PA24148 | Abfrontier | 50 ul | EUR 400.8 |
Description: Mouse polyclonal to Human Milk Fat Globule 1 |
anti-Human Milk Fat Globule 1 |
|||
YF-PA13135 | Abfrontier | 50 ug | EUR 435.6 |
Description: Mouse polyclonal to Human Milk Fat Globule 1 |
anti-Human Milk Fat Globule 1 |
|||
YF-PA13136 | Abfrontier | 100 ul | EUR 483.6 |
Description: Rabbit polyclonal to Human Milk Fat Globule 1 |
anti-Human Milk Fat Globule 1 |
|||
YF-PA13137 | Abfrontier | 100 ug | EUR 483.6 |
Description: Rabbit polyclonal to Human Milk Fat Globule 1 |
Anti-Human Milk Fat Globule 1/MFGE8 Antibody |
|||
PA1945 | BosterBio | 100ug/vial | EUR 400.8 |
Anti-ACADL-Specific antibody |
|||
PAab00064 | Lifescience Market | 100 ug | EUR 426 |
Anti-ACTA1-Specific antibody |
|||
PAab00115 | Lifescience Market | 100 ug | EUR 426 |
Anti-ADAM17-Specific antibody |
|||
PAab00139 | Lifescience Market | 100 ug | EUR 426 |
Anti-ADRA1A-Specific antibody |
|||
PAab00177 | Lifescience Market | 100 ug | EUR 426 |
Anti-ADRA2B-Specific antibody |
|||
PAab00179 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-AFF1-Specific antibody |
|||
PAab00195 | Lifescience Market | 100 ug | EUR 426 |
Anti-AKAP11-Specific antibody |
|||
PAab00251 | Lifescience Market | 100 ug | EUR 426 |
Anti-AMPD1-Specific antibody |
|||
PAab00370 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-ARF5-Specific antibody |
|||
PAab00534 | Lifescience Market | 100 ug | EUR 426 |
Anti-ARF6-Specific antibody |
|||
PAab00535 | Lifescience Market | 100 ug | EUR 426 |
Anti-ARHGEF9-Specific antibody |
|||
PAab00565 | Lifescience Market | 100 ug | EUR 426 |
Anti-ARSK-Specific antibody |
|||
PAab00613 | Lifescience Market | 100 ug | EUR 426 |
Anti-ATF2-Specific antibody |
|||
PAab00661 | Lifescience Market | 100 ug | EUR 426 |
Anti-ATP1A1-Specific antibody |
|||
PAab00692 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-ATP1A2-Specific antibody |
|||
PAab00694 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-ATP5G2-Specific antibody |
|||
PAab00708 | Lifescience Market | 100 ug | EUR 426 |
Anti-BAG1S-specific antibody |
|||
PAab00788 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-BAI2-Specific antibody |
|||
PAab00791 | Lifescience Market | 100 ug | EUR 426 |
Anti-BAI3-Specific antibody |
|||
PAab00792 | Lifescience Market | 100 ug | EUR 426 |
Anti-Barkor-Specific antibody |
|||
PAab00806 | Lifescience Market | 100 ug | EUR 426 |
Anti-BLOC1S1-Specific antibody |
|||
PAab00909 | Lifescience Market | 100 ug | EUR 426 |
Anti-BRN2-Specific antibody |
|||
PAab00963 | Lifescience Market | 100 ug | EUR 426 |
Anti-BTF3L3-Specific antibody |
|||
PAab00976 | Lifescience Market | 100 ug | EUR 426 |
Anti-SLC12A5-Specific antibody |
|||
PAab07908 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-SLC25A6-Specific antibody |
|||
PAab07947 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-SLIT2-Specific antibody |
|||
PAab07981 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-SMYD1-Specific antibody |
|||
PAab08047 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-Somatostatin-Specific antibody |
|||
PAab08109 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-SPAG4-Specific antibody |
|||
PAab08142 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-SPIN1-Specific antibody |
|||
PAab08178 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-SPTBN1-Specific antibody |
|||
PAab08204 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-SRGAP3-Specific antibody |
|||
PAab08227 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-ST8SIA2-Specific antibody |
|||
PAab08276 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-STEAP2-Specific antibody |
|||
PAab08317 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-SURVIVIN-Specific antibody |
|||
PAab08403 | Lifescience Market | 100 ug | EUR 426 |
Anti-SYN1-Specific antibody |
|||
PAab08416 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-TAF1-Specific antibody |
|||
PAab08484 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-TDRKH specific antibody |
|||
PAab08580 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-TGFBR3-Specific antibody |
|||
PAab08645 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-TINAG-Specific antibody |
|||
PAab08712 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-TMF1-Specific antibody |
|||
PAab08796 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-TOP2A-Specific antibody |
|||
PAab08868 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-Tuberin-Specific antibody |
|||
PAab09101 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-TWIST1-specific antibody |
|||
PAab09118 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-UBASH3A-Specific antibody |
|||
PAab09150 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-UBC9-Specific antibody |
|||
PAab09159 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-UBE2D1-Specific antibody |
|||
PAab09167 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-UBN1-Specific antibody |
|||
PAab09202 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-UNC5C-Specific antibody |
|||
PAab09263 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-UNC5D-Specific antibody |
|||
PAab09264 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-URB1-Specific antibody |
|||
PAab09286 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-WASF4-Specific antibody |
|||
PAab09469 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-YES1-Specific antibody |
|||
PAab09563 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-ZIC4-Specific antibody |
|||
PAab09637 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-ZNF600-Specific antibody |
|||
PAab09718 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-ZNRF2-Specific antibody |
|||
PAab09746 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-CAPG-Specific antibody |
|||
PAab01249 | Lifescience Market | 100 ug | EUR 426 |
Anti-Catalase-Specific antibody |
|||
PAab01302 | Lifescience Market | 100 ug | EUR 426 |
Anti-CCKAR-specific antibody |
|||
PAab01377 | Lifescience Market | 100 ug | EUR 426 |
Anti-CCKBR-specific antibody |
|||
PAab01378 | Lifescience Market | 100 ug | EUR 426 |
Anti-CCR2-specific antibody |
|||
PAab01390 | Lifescience Market | 100 ug | EUR 426 |
Anti-CCT6A-Specific antibody |
|||
PAab01401 | Lifescience Market | 100 ug | EUR 426 |
Anti-CD68-Specific antibody |
|||
PAab01493 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-CDH10-specific antibody |
|||
PAab01546 | Lifescience Market | 100 ug | EUR 426 |
Anti-CDK1-Specific antibody |
|||
PAab01552 | Lifescience Market | 100 ug | EUR 426 |
Anti-CEACAM3-Specific antibody |
|||
PAab01578 | Lifescience Market | 100 ug | EUR 426 |
Anti-CEP350-Specific antibody |
|||
PAab01603 | Lifescience Market | 100 ug | EUR 426 |
Anti-CES7-Specific antibody |
|||
PAab01618 | Lifescience Market | 100 ug | EUR 426 |
Anti-CHST13-Specific antibody |
|||
PAab01693 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-CPNE9-Specific antibody |
|||
PAab01932 | Lifescience Market | 100 ug | EUR 426 |
Anti-CPT1B-specific antibody |
|||
PAab01944 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-CPT1C-specific antibody |
|||
PAab01946 | Lifescience Market | 100 ug | EUR 426 |
Anti-CRLS1-Specific antibody |
|||
PAab01983 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-CST2-Specific antibody |
|||
PAab02033 | Lifescience Market | 100 ug | EUR 426 |
Anti-CSTL1-Specific antibody |
|||
PAab02041 | Lifescience Market | 100 ug | EUR 426 |
Anti-CUL4A-Specific antibody |
|||
PAab02078 | Lifescience Market | 100 ug | EUR 426 |
Anti-CXCR7-Specific antibody |
|||
PAab02107 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-CYP1A2-Specific antibody |
|||
PAab02148 | Lifescience Market | 100 ug | EUR 426 |
Anti-CYP2E1-Specific antibody |
|||
PAab02159 | Lifescience Market | 100 ug | EUR 426 |
Anti-CYP4F11-Specific antibody |
|||
PAab02171 | Lifescience Market | 100 ug | EUR 426 |
Anti-CYP4Z1-Specific antibody |
|||
PAab02175 | Lifescience Market | 100 ug | EUR 426 |
Anti-DAPK2-Specific antibody |
|||
PAab02241 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-DCC-Specific antibody |
|||
PAab02262 | Lifescience Market | 100 ug | EUR 426 |
Anti-DGKK-Specific antibody |
|||
PAab02360 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-DLL1-Specific antibody |
|||
PAab02415 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-DOCK180-Specific antibody |
|||
PAab02493 | Lifescience Market | 100 ug | EUR 426 |
Anti-DR5-Specific antibody |
|||
PAab02530 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-EDG7-Specific antibody |
|||
PAab02635 | Lifescience Market | 100 ug | EUR 426 |
Anti-EGFR-Specific antibody |
|||
PAab02669 | Lifescience Market | 100 ug | EUR 426 |
Anti-EIF2C1-Specific antibody |
|||
PAab02697 | Lifescience Market | 100 ug | EUR 426 |
Anti-EIF2C3-Specific antibody |
|||
PAab02698 | Lifescience Market | 100 ug | EUR 426 |
Anti-EPHA1-specific antibody |
|||
PAab02801 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-EPHA6-Specific antibody |
|||
PAab02804 | Lifescience Market | 100 ug | EUR 426 |
Anti-FABP7-Specific antibody |
|||
PAab02937 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-FANCA-Specific antibody |
|||
PAab03004 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-FcRn-Specific antibody |
|||
PAab03063 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-FGF16-Specific antibody |
|||
PAab03091 | Lifescience Market | 100 ug | EUR 426 |
Anti-FMO2-specific antibody |
|||
PAab03169 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-FMO5-specific antibody |
|||
PAab03171 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-FOXH1-Specific antibody |
|||
PAab03196 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-FOXL2-Specific antibody |
|||
PAab03199 | Lifescience Market | 100 ug | EUR 426 |
Anti-GAB3-Specific antibody |
|||
PAab03273 | Lifescience Market | 100 ug | EUR 426 |
Anti-GABARAPL1-Specific antibody |
|||
PAab03276 | Lifescience Market | 100 ug | EUR 426 |
Anti-GABARAPL2-Specific antibody |
|||
PAab03278 | Lifescience Market | 100 ug | EUR 426 |
Anti-GAC-specific antibody |
|||
PAab03290 | Lifescience Market | 100 ug | EUR 426 |
Anti-GATA4-Specific antibody |
|||
PAab03363 | Lifescience Market | 100 ug | EUR 426 |
Anti-GEFT-Specific antibody |
|||
PAab03416 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-GLI2-Specific antibody |
|||
PAab03477 | Lifescience Market | 100 ug | EUR 426 |
Anti-GLI3-Specific antibody |
|||
PAab03478 | Lifescience Market | 100 ug | EUR 426 |
Anti-GPR101-Specific antibody |
|||
PAab03587 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-GPR123-Specific antibody |
|||
PAab03592 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-GPR139-Specific antibody |
|||
PAab03596 | Lifescience Market | 100 ug | EUR 426 |
Anti-GPRASP1-Specific antibody |
|||
PAab03612 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-GPRIN3-Specific antibody |
|||
PAab03616 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-HBA1-Specific antibody |
|||
PAab03767 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-HBG1-Specific antibody |
|||
PAab03771 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-HBM-Specific antibody |
|||
PAab03773 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-HBQ1-Specific antibody |
|||
PAab03776 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-HBZ-Specific antibody |
|||
PAab03780 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-HDAC1-specific antibody |
|||
PAab03795 | Lifescience Market | 100 ug | EUR 426 |
Anti-HDAC2-specific antibody |
|||
PAab03797 | Lifescience Market | 100 ug | EUR 426 |
Anti-HDAC3-specific antibody |
|||
PAab03799 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-HDAC4-specific antibody |
|||
PAab03801 | Lifescience Market | 100 ug | EUR 426 |
Anti-HDAC5-specific antibody |
|||
PAab03802 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-HDAC6-specific antibody |
|||
PAab03804 | Lifescience Market | 100 ug | EUR 426 |
Anti-HIP1-Specific antibody |
|||
PAab03870 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-HMMR-Specific antibody |
|||
PAab03936 | Lifescience Market | 100 ug | EUR 426 |
Anti-HNRNPUL2-Specific antibody |
|||
PAab03961 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-HRAS-Specific antibody |
|||
PAab04008 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-HSPG2-Specific antibody |
|||
PAab04063 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-IGF1A-Specific antibody |
|||
PAab04168 | Lifescience Market | 100 ug | EUR 426 |
Anti-IGF1B-Specific antibody |
|||
PAab04169 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-IGF1R-Specific antibody |
|||
PAab04170 | Lifescience Market | 100 ug | EUR 426 |
Anti-IGF2R-Specific antibody |
|||
PAab04174 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-ING1-specific antibody |
|||
PAab04309 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-ING3-specific antibody |
|||
PAab04312 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-ING4-specific antibody |
|||
PAab04314 | Lifescience Market | 100 ug | EUR 426 |
Anti-ITPR1-specific antibody |
|||
PAab04425 | Lifescience Market | 100 ug | EUR 426 |
Anti-KCNB1-Specific antibody |
|||
PAab04480 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-KGA-Specific antibody |
|||
PAab04520 | Lifescience Market | 100 ug | EUR 426 |
Anti-KISS1R-Specific antibody |
|||
PAab04593 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-KLHL14-Specific antibody |
|||
PAab04614 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-KRT10-specific antibody |
|||
PAab04649 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-Kv1.4-Specific antibody |
|||
PAab04664 | Lifescience Market | 100 ug | EUR 426 |
Anti-LAMC3-Specific antibody |
|||
PAab04680 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-LATS2-Specific antibody |
|||
PAab04709 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-LC3A-Specific antibody |
|||
PAab04719 | Lifescience Market | 100 ug | EUR 426 |
Anti-LC3B-Specific antibody |
|||
PAab04720 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-LDHA-Specific antibody |
|||
PAab04737 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-LDHB-Specific antibody |
|||
PAab04739 | Lifescience Market | 100 ug | EUR 426 |
Anti-LDHC-Specific antibody |
|||
PAab04740 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-Lin28A-specific antibody |
|||
PAab04784 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-Lin28B-specific antibody |
|||
PAab04786 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-LRP2-Specific antibody |
|||
PAab04847 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-MAS1L-Specific antibody |
|||
PAab05020 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-MCL1L-specific antibody |
|||
PAab05054 | Lifescience Market | 100 ug | EUR 426 |
Anti-MDM1-Specific antibody |
|||
PAab05076 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-MEF2C-Specific antibody |
|||
PAab05107 | Lifescience Market | 100 ug | EUR 426 |
Anti-MYH10-Specific antibody |
|||
PAab05472 | Lifescience Market | 100 ug | EUR 426 |
Anti-MYH4-Specific antibody |
|||
PAab05476 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-MYH7-specific antibody |
|||
PAab05478 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-PLOD2-Specific antibody |
|||
PAab06552 | Lifescience Market | 100 ug | EUR 426 |
Anti-POLR2B-Specific antibody |
|||
PAab06620 | Lifescience Market | 100 ug | EUR 426 |
Induction of protecting immune responses in opposition to a deadly Zika virus problem post-vaccination with a twin serotype of recombinant vesicular stomatitis virus carrying the genetically modified Zika virus E protein gene
The event of a vaccine to forestall Zika virus (ZIKV) an infection has been one of many priorities in infectious illness analysis lately. There have been quite a few makes an attempt to develop an efficient vaccine in opposition to ZIKV. It’s crucial to decide on the most secure and the best ZIKV vaccine from all candidate vaccines to manage this an infection globally. We’ve employed a twin serotype of prime-boost recombinant vesicular stomatitis virus (VSV) vaccine technique, to develop a ZIKV vaccine candidate, utilizing a kind 1 IFN-receptor knock-out (Ifnar -/-) mouse mannequin for problem research.
Prime vaccination with an attenuated recombinant VSV Indiana serotype (rVSVInd) carrying a genetically modified ZIKV envelope (E) protein gene adopted by enhance vaccination with attenuated recombinant VSV New Jersey serotype (rVSVNJ) carrying the identical E gene induced sturdy adaptive immune responses. Particularly, rVSV carrying the ZIKV E gene with the honeybee melittin sign peptide (msp) on the N terminus and VSV G protein transmembrane area and cytoplasmic tail (Gtc) on the C terminus of the E gene induced robust protecting immune responses. This vaccine routine induced extremely potent neutralizing antibodies and T cell responses within the absence of an adjuvant and guarded Ifnar -/- mice from a deadly dose of the ZIKV problem.
Chilly-inducible RNA-binding protein (CIRP) potentiates uric acid-induced IL-1β manufacturing
Background: Gout is an autoinflammatory illness pushed by interleukin-1 (IL-1) induction in response to uric acid crystals. IL-1β manufacturing relies on inflammasome activation, which requires a priming sign, adopted by an activating sign. The cold-inducible RNA-binding protein (CIRP) has been not too long ago recognized as a damage-associated molecular sample (DAMP). On this research, we evaluated the roles of CIRP in monosodium urate (MSU)-mediated IL-1β secretion utilizing human neutrophils.
Strategies: Human neutrophils had been stimulated by MSU within the presence or absence of CIRP priming to find out NLRP3 inflammasome activation and subsequent caspase-1 activation and IL-1β manufacturing. Mobile supernatants had been analyzed by enzyme-linked immunosorbent assay (ELISA) to find out the presence of IL-1β or caspase-1 (p20). The mobile supernatants and lysates had been additionally analyzed by immunoblotting utilizing anti-cleaved IL-1β or anti-cleaved caspase-1 antibodies.
Outcomes: Neither CIRP nor MSU stimulation alone induced ample IL-1β secretion from neutrophils. Nevertheless, MSU stimulation induced IL-1β secretion from CIRP-primed neutrophils in a dose-dependent method. This MSU-induced IL-1β secretion from CIRP-primed neutrophils was accompanied by the induction of cleaved IL-1β (p17), which was inhibited by the pretreatment of MCC950, a selected inhibitor for NLRP3. Moreover, cleaved caspase-1 was induced within the mobile lysates of CIRP/MSU-treated neutrophils. Moreover, CIRP stimulation induced the protein expression of pro-IL-1β in neutrophils.
Conclusions: Our knowledge point out that CIRP, an endogenous stress molecule, triggers uric acid-induced mature IL-1β induction as a priming stimulus for NLRP3 inflammasome in human neutrophils. We suggest that CIRP acts as an necessary proinflammatory stimulant that primes and prompts inflammasome and pro-IL-1β processing in response to uric acid in innate immune cells.
HDAC-8, human recombinant |
|||
7618-100 | Biovision | EUR 705.6 |
HDAC-8, human recombinant |
|||
7618-1000 | Biovision | EUR 5214 |
HDAC-8, human recombinant |
|||
7618-20 | Biovision | EUR 314.4 |
HDAC 3 antibody |
|||
20R-1663 | Fitzgerald | 100 ug | EUR 807.6 |
Description: Rabbit polyclonal HDAC 3 antibody |
HDAC-IN-3 |
|||
HY-19772 | MedChemExpress | 50mg | EUR 2539.2 |
NCOR2/ Rat NCOR2 ELISA Kit |
|||
ELA-E11288r | Lifescience Market | 96 Tests | EUR 1063.2 |
HDAC-3 Blocking Peptide |
|||
3603BP-50 | Biovision | EUR 183.6 |
HDAC 3 Blocking Peptide |
|||
33R-10518 | Fitzgerald | 50 ug | EUR 418.8 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of HDAC 3 antibody, catalog no. 20R-1663 |
NCOR2 Antibody |
|||
43109-100ul | SAB | 100ul | EUR 302.4 |
NCOR2 antibody |
|||
70R-18789 | Fitzgerald | 50 ul | EUR 522 |
Description: Rabbit polyclonal NCOR2 antibody |
NCOR2 antibody |
|||
70R-32241 | Fitzgerald | 100 ug | EUR 392.4 |
Description: Rabbit polyclonal NCOR2 antibody |
NCOR2 Antibody |
|||
ABD8896 | Lifescience Market | 100 ug | EUR 525.6 |
NCOR2 Antibody |
|||
1-CSB-PA080039 | Cusabio |
|
|
Description: A polyclonal antibody against NCOR2. Recognizes NCOR2 from Human. This antibody is Unconjugated. Tested in the following application: IHC, IF, ELISA;IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/20000 |
NCOR2 siRNA |
|||
20-abx925532 | Abbexa |
|
|
NCOR2 siRNA |
|||
20-abx925533 | Abbexa |
|
|
NCOR2 Antibody |
|||
1-CSB-PA015548GA01HU | Cusabio |
|
|
Description: A polyclonal antibody against NCOR2. Recognizes NCOR2 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB |
NCOR2 Antibody |
|||
DF8896 | Affbiotech | 200ul | EUR 420 |
NCOR2 antibody |
|||
PAab10069 | Lifescience Market | 100 ug | EUR 463.2 |
anti-NCOR2 |
|||
YF-PA25381 | Abfrontier | 50 ul | EUR 400.8 |
Description: Mouse polyclonal to NCOR2 |
Recombinant TMPRSS2 Protein, Partial |
|||
E80017 | EpiGentek |
|
|
Human NCOR2 shRNA Plasmid |
|||
20-abx956396 | Abbexa |
|
|
NCOR2 ELISA KIT|Human |
|||
EF000574 | Lifescience Market | 96 Tests | EUR 826.8 |
Human NCOR2 ELISA Kit |
|||
ELA-E0334h | Lifescience Market | 96 Tests | EUR 988.8 |
Recombinant Transmembrane Protease Serine 2 Protein, Partial |
|||
E80016 | EpiGentek |
|
|
Recombinant Novel Coronavirus Spike Glycoprotein(S), Partial |
|||
E80018 | EpiGentek |
|
|
Recombinant Human MMP-3 Protein |
|||
PROTP08254-3 | BosterBio | 10ug | EUR 380.4 |
Description: Matrix metalloproteinases (MMPs) are a family of endoproteases that require zinc and calcium for expressing catalytic activity. These enzymes play a central role in the maintenance and remodeling of the extracellular matrix. Elevated expression of their activity, caused either by up-regulation of their expression or down-regulation of their cognate inhibitors, has been implicated in various degenerative disorders, including arthritis, cardiovascular disease, skeletal growth-plate disorders, and cancer metastasis. MMP-3 degrades fibronectin, laminin, collagens III, IV, and X, and cartilage proteoglycans. Recombinant human MMP-3 is a 42.8 kDa protein containing the entire catalytic N-terminal domain and the C-terminal domain (378 amino acids). |
HDAC ELISA KIT|Human |
|||
EF010966 | Lifescience Market | 96 Tests | EUR 826.8 |
NCOR2 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
K1400604 | ABM | 1.0 ug DNA | EUR 184.8 |
IL-3 Interleukin-3 Human Recombinant Protein, His Tag |
|||
PROTP08700-3 | BosterBio | Regular: 50ug | EUR 380.4 |
Description: Interleukin-3 Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 154 amino acids fragment (20-152) and having a total molecular mass of 17.3kDa and fused with a 20 aa N-terminal His tag. ;The IL3 His is purified by proprietary chromatographic techniques. |
NCOR2 Rabbit pAb |
|||
A8388-100ul | Abclonal | 100 ul | EUR 369.6 |
NCOR2 Rabbit pAb |
|||
A8388-200ul | Abclonal | 200 ul | EUR 550.8 |
NCOR2 Rabbit pAb |
|||
A8388-20ul | Abclonal | 20 ul | EUR 219.6 |
NCOR2 Rabbit pAb |
|||
A8388-50ul | Abclonal | 50 ul | EUR 267.6 |
NCOR2 Conjugated Antibody |
|||
C43109 | SAB | 100ul | EUR 476.4 |
NCOR2 Blocking Peptide |
|||
DF8896-BP | Affbiotech | 1mg | EUR 234 |
Anti-NCOR2 antibody |
|||
PAab05594 | Lifescience Market | 100 ug | EUR 426 |
anti- NCOR2 antibody |
|||
FNab05594 | FN Test | 100µg | EUR 606.3 |
Description: Antibody raised against NCOR2 |
anti- NCOR2 antibody |
|||
FNab10069 | FN Test | 100µg | EUR 658.5 |
Description: Antibody raised against NCOR2 |
Anti-NCOR2 antibody |
|||
STJ110686 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene encodes a nuclear receptor co-repressor that mediates transcriptional silencing of certain target genes. The encoded protein is a member of a family of thyroid hormone- and retinoic acid receptor-associated co-repressors. This protein acts as part of a multisubunit complex which includes histone deacetylases to modify chromatin structure that prevents basal transcriptional activity of target genes. Aberrant expression of this gene is associated with certain cancers. Alternate splicing results in multiple transcript variants encoding different isoforms. |
PRMT1, human recombinant (Active) |
|||
4865-10 | Biovision | EUR 183.6 |
PRMT1, human recombinant (Active) |
|||
4865-1000 | Biovision | EUR 4600.8 |
PRMT1, human recombinant (Active) |
|||
4865-50 | Biovision | EUR 470.4 |
HER2, Active, Human Recombinant |
|||
8011-5 | Biovision | EUR 288 |
HER2, Active, Human Recombinant |
|||
8011-50 | Biovision | EUR 1358.4 |
Active AHCY, human recombinant |
|||
7527-10 | Biovision | EUR 314.4 |
Active AHCY, human recombinant |
|||
7527-1000 | Biovision | EUR 6578.4 |
Active AHCY, human recombinant |
|||
7527-50 | Biovision | EUR 574.8 |
Active Recombinant Human CETP |
|||
7606-100 | Biovision | EUR 966 |
Active Recombinant Human CETP |
|||
7606-1000 | Biovision | EUR 5214 |
Active Recombinant Human CETP |
|||
7606-20 | Biovision | EUR 314.4 |
Active SIRT2, human recombinant |
|||
7698-10 | Biovision | EUR 314.4 |
Active SIRT2, human recombinant |
|||
7698-1000 | Biovision | EUR 5272.8 |
Active SIRT2, human recombinant |
|||
7698-50 | Biovision | EUR 548.4 |
Active SIRT7, human recombinant |
|||
7846-10 | Biovision | EUR 261.6 |
Active SIRT7, human recombinant |
|||
7846-50 | Biovision | EUR 705.6 |
Irisin, Active, human recombinant |
|||
7852-10 | Biovision | EUR 444 |
Irisin, Active, human recombinant |
|||
7852-50 | Biovision | EUR 1292.4 |
GAPDH, Active, human recombinant |
|||
P1100-10 | Biovision | EUR 170.4 |
GAPDH, Active, human recombinant |
|||
P1100-50 | Biovision | EUR 470.4 |
HDAC Assay Kit |
|||
55R-1371 | Fitzgerald | 100 assays | EUR 807.6 |
Description: Assay Kit for detection of HDAC in the research laboratory |
HDAC Assay Kit |
|||
55R-1372 | Fitzgerald | 100 assays | EUR 807.6 |
Description: Assay Kit for detection of HDAC in the research laboratory |
HDAC 1 antibody |
|||
20R-1661 | Fitzgerald | 100 ug | EUR 807.6 |
Description: Rabbit polyclonal HDAC 1 antibody |
HDAC 2 antibody |
|||
20R-1662 | Fitzgerald | 100 ug | EUR 807.6 |
Description: Rabbit polyclonal HDAC 2 antibody |
HDAC 4 antibody |
|||
20R-1664 | Fitzgerald | 100 ug | EUR 794.4 |
Description: Rabbit polyclonal HDAC 4 antibody |
HDAC 4 antibody |
|||
20R-1665 | Fitzgerald | 100 ug | EUR 807.6 |
Description: Rabbit polyclonal HDAC 4 antibody |
HDAC 5 antibody |
|||
20R-1666 | Fitzgerald | 100 ug | EUR 794.4 |
Description: Rabbit polyclonal HDAC 5 antibody |
HDAC 6 antibody |
|||
20R-1667 | Fitzgerald | 100 ug | EUR 754.8 |
Description: Rabbit polyclonal HDAC 6 antibody |
HDAC 7 antibody |
|||
20R-1668 | Fitzgerald | 100 ug | EUR 754.8 |
Description: Rabbit polyclonal HDAC 7 antibody |
HDAC 8 antibody |
|||
20R-1669 | Fitzgerald | 100 ug | EUR 754.8 |
Description: Rabbit polyclonal HDAC 8 antibody |
HDAC 9 antibody |
|||
20R-1670 | Fitzgerald | 100 ug | EUR 781.2 |
Description: Rabbit polyclonal HDAC 9 antibody |
HDAC 10 antibody |
|||
20R-1671 | Fitzgerald | 100 ug | EUR 754.8 |
Description: Rabbit polyclonal HDAC 10 antibody |
HDAC 11 antibody |
|||
20R-1672 | Fitzgerald | 100 ug | EUR 781.2 |
Description: Rabbit polyclonal HDAC 11 antibody |
HDAC Substrate, Colorimetric |
|||
2207-100 | Biovision | EUR 360 |
HDAC Substrate, Colorimetric |
|||
2207-25 | Biovision | EUR 151.2 |
HDAC Substrate, Fluorogenic |
|||
2396-25 | Biovision | EUR 614.4 |
HDAC Substrate, Fluorogenic |
|||
2396-5 | Biovision | EUR 210 |
HDAC Set I |
|||
A9906-1 | ApexBio | 1 Set | EUR 184.8 |
HDAC-IN-7 |
|||
HY-13592 | MedChemExpress | 10mM/1mL | EUR 258 |
Apicidin (HDAC inhibitor) |
|||
SIH-346-1MG | Stressmarq | 1 mg | EUR 163.2 |
Description: The substance Apicidin is a hdac inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white solid which is soluble in 10 mg/ml DMSO or 100% Ethanol. |
Apicidin (HDAC inhibitor) |
|||
SIH-346-5MG | Stressmarq | 5 mg | EUR 408 |
Description: The substance Apicidin is a hdac inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white solid which is soluble in 10 mg/ml DMSO or 100% Ethanol. |
HPA (HDAC inhibitor) |
|||
SIH-356-10MG | Stressmarq | 10 mg | EUR 153.6 |
Description: The substance HPA is a hdac inhibitor. It is synthetically produced and has a purity of >97%. The pure substance is colorless oil which is soluble in 25 mg/ml DMSO or 25 mg/ml Ethanol. |
HPA (HDAC inhibitor) |
|||
SIH-356-50MG | Stressmarq | 50 mg | EUR 271.2 |
Description: The substance HPA is a hdac inhibitor. It is synthetically produced and has a purity of >97%. The pure substance is colorless oil which is soluble in 25 mg/ml DMSO or 25 mg/ml Ethanol. |
NCOR2 ELISA Kit (Human) (OKEH04298) |
|||
OKEH04298 | Aviva Systems Biology | 96 Wells | EUR 794.4 |
Description: Description of target: This gene encodes a nuclear receptor co-repressor that mediates transcriptional silencing of certain target genes. The encoded protein is a member of a family of thyroid hormone- and retinoic acid receptor-associated co-repressors. This protein acts as part of a multisubunit complex which includes histone deacetylases to modify chromatin structure that prevents basal transcriptional activity of target genes. Aberrant expression of this gene is associated with certain cancers. Alternate splicing results in multiple transcript variants encoding different isoforms.;Species reactivity: Human;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 100 pg/mL |
NCOR2 ORF Vector (Human) (pORF) |
|||
ORF025977 | ABM | 1.0 ug DNA | EUR 3276 |
PLGF3 Human, Placenta Growth Factor-3 Human Recombinant Protein, sf9 |
|||
PROTP49763-3 | BosterBio | Regular: 25ug | EUR 380.4 |
Description: PLGF3 Human Recombinant produced in Spodoptera frugiperda is a glycosylated homodimer containing 2 chains of 203 amino acids (Leu19-Arg221) and having a molecular mass of 58kDa.;The PLGF-3 is purified by proprietary chromatographic techniques. |
TGF-b-3 Transforming Growth Factor-Beta 3 Human Recombinant Protein, Plant |
|||
PROTP10600-3 | BosterBio | Regular: 5ug | EUR 380.4 |
Description: TGFB3 Human Recombinant produced in plant is a disulfide-linked homodimeric, glycosylated, polypeptide chain containing 118 amino acids and having a molecular mass of 27.2kDa. ;The TGFB3 is fused to 6xHis tag at N-terminus and purified by standard chromatographic techniques. |
Active Blocker 3 |
|||
abx090803-01g | Abbexa | 0.1 g | EUR 493.2 |
Caspase-3, active |
|||
RA15046 | Neuromics | 50 ug | EUR 459.6 |
Recombinant Human Activin-A Active |
|||
7-00004 | CHI Scientific | 1ug | Ask for price |
Recombinant Human Activin-A Active |
|||
7-00005 | CHI Scientific | 5ug | Ask for price |
Recombinant Human Activin-A Active |
|||
7-00006 | CHI Scientific | 100µg | Ask for price |
Recombinant Human Activin-B Active |
|||
7-00010 | CHI Scientific | 1ug | Ask for price |
Recombinant Human Activin-B Active |
|||
7-00011 | CHI Scientific | 5ug | Ask for price |
Recombinant Human Activin-B Active |
|||
7-00012 | CHI Scientific | 100µg | Ask for price |
MMP-14, Active, Human Recombinant |
|||
8009-10 | Biovision | EUR 379.2 |
MMP-14, Active, Human Recombinant |
|||
8009-50 | Biovision | EUR 966 |
Active Cathepsin D, Human Recombinant |
|||
9229-10 | Biovision | EUR 294 |
Active Cathepsin D, Human Recombinant |
|||
9229-100 | Biovision | EUR 1358.4 |
Active Cathepsin D, Human Recombinant |
|||
9229-50 | Biovision | EUR 882 |
Active Cathepsin S, human recombinant |
|||
7526-10 | Biovision | EUR 405.6 |
Active Cathepsin S, human recombinant |
|||
7526-50 | Biovision | EUR 1351.2 |
Active Cathepsin S, human recombinant |
|||
7526-500 | Biovision | EUR 10956 |
Active Cathepsin B, human recombinant |
|||
7580-1000 | Biovision | EUR 11739.6 |
Active Cathepsin B, human recombinant |
|||
7580-5 | Biovision | EUR 352.8 |
Active Cathepsin B, human recombinant |
|||
7580-50 | Biovision | EUR 1358.4 |
Cathepsin K, Active, human recombinant |
|||
7600-5 | Biovision | EUR 470.4 |
Cathepsin K, Active, human recombinant |
|||
7600-50 | Biovision | EUR 2734.8 |
MMP-9, Active, human recombinant |
|||
7867-1000 | Biovision | EUR 601.2 |
MMP-9, Active, human recombinant |
|||
7867-500 | Biovision | EUR 398.4 |
Active BCL2L1 Protein, human recombinant |
|||
7885-10 | Biovision | EUR 307.2 |
Active BCL2L1 Protein, human recombinant |
|||
7885-50 | Biovision | EUR 829.2 |
5-Lipoxygenase, Active, Human Recombinant |
|||
P1373-200 | Biovision | EUR 379.2 |
MMP-9, Active, Human Recombinant |
|||
P1567-10 | Biovision | 10 µg | EUR 417.6 |
MMP-9, Active, Human Recombinant |
|||
P1567-50 | Biovision | 50 µg | EUR 612 |
Mouse NCOR2 shRNA Plasmid |
|||
20-abx972783 | Abbexa |
|
|
HDAC-1 Blocking Peptide |
|||
3601BP-50 | Biovision | EUR 183.6 |
HDAC-2 Blocking Peptide |
|||
3602BP-50 | Biovision | EUR 183.6 |
HDAC-4 Blocking Peptide |
|||
3604BP-50 | Biovision | EUR 183.6 |
HDAC-5 Blocking Peptide |
|||
3605BP-50 | Biovision | EUR 183.6 |
HDAC-6 Blocking Peptide |
|||
3606BP-50 | Biovision | EUR 183.6 |
HDAC-7 Blocking Peptide |
|||
3607BP-50 | Biovision | EUR 183.6 |
HDAC-8 Blocking Peptide |
|||
3608BP-50 | Biovision | EUR 183.6 |
HDAC-9 Blocking Peptide |
|||
3609BP-50 | Biovision | EUR 183.6 |
HDAC-10 Blocking Peptide |
|||
3610BP-50 | Biovision | EUR 183.6 |
HDAC-11 Blocking Peptide |
|||
3611BP-50 | Biovision | EUR 183.6 |
HDAC 1 Blocking Peptide |
|||
33R-10516 | Fitzgerald | 50 ug | EUR 418.8 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of HDAC 1 antibody, catalog no. 20R-1661 |
HDAC 2 Blocking Peptide |
|||
33R-10517 | Fitzgerald | 50 ug | EUR 418.8 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of HDAC 2 antibody, catalog no. 20R-1662 |
HDAC 4 Blocking Peptide |
|||
33R-10519 | Fitzgerald | 50 ug | EUR 418.8 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of HDAC 4 antibody, catalog no. 20R-1664 |
HDAC 5 Blocking Peptide |
|||
33R-10520 | Fitzgerald | 50 ug | EUR 418.8 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of HDAC 5 antibody, catalog no. 20R-1666 |
HDAC 6 Blocking Peptide |
|||
33R-10521 | Fitzgerald | 50 ug | EUR 418.8 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of HDAC 6 antibody, catalog no. 20R-1667 |
HDAC 7 Blocking Peptide |
|||
33R-10522 | Fitzgerald | 50 ug | EUR 418.8 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of HDAC 7 antibody, catalog no. 20R-1668 |
HDAC 8 Blocking Peptide |
|||
33R-10523 | Fitzgerald | 50 ug | EUR 418.8 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of HDAC 8 antibody, catalog no. 20R-1669 |
HDAC 9 Blocking Peptide |
|||
33R-10524 | Fitzgerald | 50 ug | EUR 418.8 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of HDAC 9 antibody, catalog no. 20R-1670 |
HDAC 10 Blocking Peptide |
|||
33R-10525 | Fitzgerald | 50 ug | EUR 418.8 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of HDAC 10 antibody, catalog no. 20R-1671 |
HDAC 11 Blocking Peptide |
|||
33R-10526 | Fitzgerald | 50 ug | EUR 418.8 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of HDAC 11 antibody, catalog no. 20R-1672 |
HDAC Substrate II, Colorimetric |
|||
2395-25 | Biovision | EUR 548.4 |
HDAC Substrate II, Colorimetric |
|||
2395-5 | Biovision | EUR 183.6 |
AR-42 (HDAC-42) |
|||
2716-1 | Biovision | EUR 183.6 |
AR-42 (HDAC-42) |
|||
2716-5 | Biovision | EUR 548.4 |
DiscoveryPak? HDAC Inhibitor Set |
|||
K851-6 | Biovision | EUR 823.2 |
JAK/HDAC-IN-1 |
|||
HY-126141 | MedChemExpress | 10mM/1mL | EUR 286.8 |
HDAC Family Antibody Set |
|||
K333-11-30 | Biovision | EUR 1488 |
Trichostatin A (HDAC inhibitor) |
|||
SIH-254-1MG | Stressmarq | 1 mg | EUR 247.2 |
Description: The substance Trichostatin A is a hdac inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is beige solid which is soluble to 10 mM in ethanol and to 50 mM in DMSO. |
Trichostatin A (HDAC inhibitor) |
|||
SIH-254-5MG | Stressmarq | 5 mg | EUR 735.6 |
Description: The substance Trichostatin A is a hdac inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is beige solid which is soluble to 10 mM in ethanol and to 50 mM in DMSO. |
Phenylbutyrate Na (HDAC inhibitor) |
|||
SIH-255-100MG | Stressmarq | 100 mg | EUR 111.6 |
Description: The substance Phenylbutyrate Na is a hdac inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white solid which is soluble to 1100 mM in water and 100 mM in DMSO. |
Phenylbutyrate Na (HDAC inhibitor) |
|||
SIH-255-500MG | Stressmarq | 500 mg | EUR 152.4 |
Description: The substance Phenylbutyrate Na is a hdac inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white solid which is soluble to 1100 mM in water and 100 mM in DMSO. |
Bml-210 (HDAC inhibitor) |
|||
SIH-348-25MG | Stressmarq | 25 mg | EUR 1039.2 |
Description: The substance Bml-210 is a hdac inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is tan solid which is soluble in 25 mg/ml DMSO or 10 mg/ml Ethanol. |
Bml-210 (HDAC inhibitor) |
|||
SIH-348-5MG | Stressmarq | 5 mg | EUR 319.2 |
Description: The substance Bml-210 is a hdac inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is tan solid which is soluble in 25 mg/ml DMSO or 10 mg/ml Ethanol. |
Sodium Valproate (HDAC inhibitor) |
|||
SIH-357-5G | Stressmarq | 5 g | EUR 114 |
Description: The substance Sodium Valproate is a hdac inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white solid which is soluble in 50 mg/ml Water. |
SAHA (Vorinostat) (HDAC inhibitor) |
|||
SIH-359-250MG | Stressmarq | 250 mg | EUR 394.8 |
Description: The substance SAHA (Vorinostat) is a hdac inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white solid which is soluble in 50 mg/ml DMSO, or 2 mg/ml Ethanol. |
SAHA (Vorinostat) (HDAC inhibitor) |
|||
SIH-359-50MG | Stressmarq | 50 mg | EUR 153.6 |
Description: The substance SAHA (Vorinostat) is a hdac inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white solid which is soluble in 50 mg/ml DMSO, or 2 mg/ml Ethanol. |
MS 275 (HDAC inhibitor) |
|||
SIH-416-1MG | Stressmarq | 1 mg | EUR 205.2 |
Description: The substance MS 275 is a hdac inhibitor. It is synthetically produced and has a purity of >98.5. The pure substance is off white solid which is soluble in DMSO or methanol.. |
Human recombinant UBE2D3 |
|||
6430-3 | Biovision | EUR 438 |
Human recombinant UBE2L3 |
|||
6431-3 | Biovision | EUR 438 |
LIGHT, Human Recombinant |
|||
P1291-3 | Biovision | EUR 210 |
Recombinant Human Mitogen-Activated Protein Kinase 3, Active |
|||
7-03937 | CHI Scientific | 3µg | Ask for price |
Recombinant Human Mitogen-Activated Protein Kinase 3, Active |
|||
7-03938 | CHI Scientific | 10µg | Ask for price |
Recombinant Human Mitogen-Activated Protein Kinase 3, Active |
|||
7-03939 | CHI Scientific | 20µg | Ask for price |
NCOR2 sgRNA CRISPR Lentivector set (Human) |
|||
K1400601 | ABM | 3 x 1.0 ug | EUR 406.8 |
Human HDAC(Histone deacetylase) ELISA Kit |
|||
EH4908 | FN Test | 96T | EUR 628.92 |
Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Homo sapiens ;Sensitivity: 0.094 ng/ml |
Ncor2 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
K4359604 | ABM | 1.0 ug DNA | EUR 184.8 |
Ncor2 sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
K7301604 | ABM | 1.0 ug DNA | EUR 184.8 |
NCOR2 3'UTR GFP Stable Cell Line |
|||
TU065325 | ABM | 1.0 ml | EUR 1825.2 |
Ncor2 3'UTR GFP Stable Cell Line |
|||
TU263797 | ABM | 1.0 ml | Ask for price |
Ncor2 3'UTR Luciferase Stable Cell Line |
|||
TU113901 | ABM | 1.0 ml | Ask for price |
Ncor2 3'UTR GFP Stable Cell Line |
|||
TU163901 | ABM | 1.0 ml | Ask for price |